The 18th International Symposium on Acute Leukemias (ISALXVIII) took place from March 19-22, 2023, in Munich, Germany, and online. This symposium covered significant updates in the biology and treatment of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and acute promyelocytic leukemia (APL).
Key Highlights:
Advancements in AML Treatment: Discussions focused on personalized therapy approaches and the integration of artificial intelligence in diagnosing and managing AML.
Minimal Residual Disease (MRD): Experts addressed the current role of MRD in AML and the challenges associated with its implementation in clinical practice.
Leukemic Stem Cells: The symposium explored the prognostic value of CD34+CD38− leukemic stem cell frequency in AML, emphasizing its potential impact on treatment strategies.